Age-related macular degeneration (AMD), a leading cause of vision loss in people aged 55 years and older, causes damage to the central portion of the retina (macula) that is responsible for sharp, central vision. While the “wet” form of AMD is less common (10%-15% of cases) than the “dry,” it accounts for 90% of all cases of severe vision loss from the disease. The wet form of the disease is characterized by abnormal blood vessels under the retina that tend to break and bleed, causing the retina to lift. Fortunately, there is treatment that inhibits the growth of these blood vessels. It involves injecting bevacizumab (Avastatin) or ranibizumab (Lucentis) directly into the vitreous, the gel-like filling inside the eye.
P.S. Prior to the use of bevacizumab (Avastatin) and ranibizumab (Lucentis), “wet” AMD was treated with lasers that stopped the bleeding.